Apple (NASDAQ:AAPL): Morgan Stanley said the iPhone 5C could increase Apples market share by 13 points in China at the expense of Nokia, HTC, and Samsung. The firm said the iPhone 5C could add $4 to earnings per share and added 20 million units to its current estimates.
Weyerhaeuser (NYSE:WY): Longbow has upgraded Weyerhaeuser to Buy from Neutral. The analyst upgraded shares due to recent share weakness and expects the sale or spin-off of the real estate business to act as a near-term catalyst. Long-term, the firm expects rising forest products demand and reduced supply from Canada to drive shares higher. The price target is now $34.
Marvell (NASDAQ:MRVL): RBC Capital believes that Marvell is poised to report better than expected results, driven by share gains and increased revenue from storage devices. The firm thinks that the company is poised to report favorable results in the second half of 2013 and it keeps a Top Pick rating on the stock.
Onyx Pharmaceuticals (NASDAQ:ONXX): Brean Capital believes the recent weakness in Onyx Pharmaceuticals is a buying opportunity based on the belief a deal with Amgen (NASDAQ:AMGN) will still get done. The firm believes the results of its ASPIRE trial is more important than the FOCUS study citing feedback from several shareholders. Brean expects the results to have greater implications for Oprozomib’s potential and rates shares as Buys with a $160 price target.